Case File
efta-efta01014568DOJ Data Set 9OtherFrom: J <[email protected]>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01014568
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: J <[email protected]>
To:
Subject: Re:
Date: Mon, 03 Dec 2018 13:25:06 +0000
i can speak after 10 am. 1. separate issues are your financials and your labs . 2. have you monetized parts of
the cos? 3. lab budget. ? current and ideal? 4. why would assume that making some organs younger woudl
still be able to be controlled by an older brain?
On Mon, Dec 3, 2018 at 8:13 AM Church, George <
wrote:
I enjoyed the conversation too. Thanks for asking about the 27 cos. Most of these are either very young
newcos (15 in 2018) or I had minor/diluted shares. Also payback in biotech is slower than most investments.
Even though my Harvard lab is very frugal (reducing costs by 10 million-fold), and most our 90 employees get
paid less than $60K per year, we still have many good ideas that don't get implemented. Also, last week I
learned that our largest and longest grant won't be renewable for the very odd reason that we have been too
successful in peer-review. A few members of Congress 'might' be looking for examples of 'Center of
Excellence' teams that are getting money year after year. (Sounds like Harrison Bergeron). The
administrators are afraid that one successful lab could endanger many other grants (or even their whole
program). They aren't even that sure about the Congressional concern rumor, but this is still enough to derail
my lab renewal.
Thanks again.
--George
From: "jeffrey E." <[email protected]>
Date: Monday, December 3, 2018 at 5:01 AM
To: George Church
lots of fun yesterday , thx for coming . I was surprised to hear that with 27 cos formed you were stil
concerned about money? . would you ikke the share the details of the situation? to see if i can be helpful
please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
EFTA01014568
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA01014569
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Email
[email protected]Related Documents (6)
DOJ Data Set 10CorrespondenceUnknown
EFTA Document EFTA02059593
0p
DOJ Data Set 10CorrespondenceUnknown
EFTA Document EFTA01800346
0p
DOJ Data Set 10CorrespondenceUnknown
EFTA Document EFTA02099168
0p
DOJ Data Set 10CorrespondenceUnknown
EFTA Document EFTA01867203
0p
DOJ Data Set 9OtherUnknown
From: george church <
1p
DOJ Data Set 9OtherUnknown
From: Jeffrey Epstein <[email protected]>
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.